Odyssey Therapeutics, Inc. SEC filings ODTX
Odyssey Therapeutics, Inc. has 72 filings in SEC EDGAR's recent list, going back to Oct 14, 2021. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 23, 2026 | Jun 23, 2026 |
| 10-Q | Quarterly report | Jun 17, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
May 11, 2026 | May 7, 2026 |
| S-8 | Employee stock plan registration | May 11, 2026 | — |
| 424B4 | Prospectus | May 8, 2026 | — |
| EFFECT | Filing | May 7, 2026 | — |
| S-1MEF | Filing | May 7, 2026 | — |
| CERT | Filing | May 7, 2026 | — |
| 8-A12B | Filing | May 5, 2026 | — |
| S-1/A | Amended registration statement | May 4, 2026 | — |
| S-1 | Registration statement | Apr 17, 2026 | — |
| DRS/A | Filing | Apr 3, 2026 | — |
| DRS/A | Filing | Mar 16, 2026 | — |
| DRS | Filing | Feb 6, 2026 | — |
| D | Filing | Dec 4, 2025 | — |
| RW | Filing | Jun 9, 2025 | — |
| S-1 | Registration statement | Jan 17, 2025 | — |
| DRS/A | Filing | Dec 5, 2024 | — |
| DRS/A | Filing | Nov 18, 2024 | — |
| DRS | Filing | Oct 7, 2024 | — |
| D/A | Filing | Aug 14, 2024 | — |
| D | Filing | Dec 15, 2023 | — |
| D | Filing | Oct 27, 2022 | — |
| D | Filing | Oct 14, 2021 | — |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ODTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1882782
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.